文献速递乳腺癌

TBCRC 048扩展队列:奥拉帕利单药治疗gPALB2或sBRCA突变转移性乳腺癌的II期研究

TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2.
PubMed 文献 · J Clin Oncol · 2026-01-28

gPALB2m组客观缓解率为75%,sBRCAm组为36.7%,sBRCAm组未达到预设目标。奥拉帕利在两类突变患者中均显示活性,扩展了PARP抑制剂潜在获益人群。

要点

  • gPALB2m转移性乳腺癌患者奥拉帕利单药ORR达75%,中位PFS 9.4个月。
  • sBRCAm患者ORR为36.7%,未达到预设目标,但仍有临床意义。
  • sBRCAm携带者中,缓解者与非缓解者的突变等位基因频率无显著差异。

核心结论

  • 奥拉帕利在携带gPALB2m或sBRCAm的转移性乳腺癌患者中具有抗肿瘤活性,可能将PARP抑制剂的获益人群扩展至gBRCA1/2m携带者之外。

主要发现

  • gPALB2m组客观缓解率为75%(80%CI 60.2-86.3),临床获益率为83.3%(90%CI 65.8-94.1),中位无进展生存期为9.4个月(90%CI 8.3-13.1),中位缓解持续时间为7.0个月(90%CI 5.6-10.4)。
  • sBRCAm组(15例sBRCA1和15例sBRCA2)客观缓解率为36.7%(80%CI 24.7-50),临床获益率为53.3%(90%CI 37-69.1),中位无进展生存期为5.5个月(90%CI 2.8-8.3),中位缓解持续时间为11.2个月(90%CI 4.4-未达到)。

关键数值与推荐

  • 入组患者为任何亚型的转移性乳腺癌,具有可测量病灶,并携带gPALB2m或sBRCAm。
  • 主要终点为客观缓解率,次要终点包括18周临床获益率、无进展生存期、缓解持续时间以及sBRCAm携带者中突变等位基因频率与缓解的关系。

临床怎么用

  • 对于携带gPALB2m的转移性乳腺癌患者,奥拉帕利单药可作为潜在治疗选择。
  • 对于携带sBRCAm的转移性乳腺癌患者,奥拉帕利单药显示一定活性,但需权衡其未达到预设客观缓解率目标的情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Translational Breast Cancer Research Consortium 048 was a proof-of-principle trial demonstrating responses to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in patients (pts) with metastatic breast cancer (MBC) with germline (g) PALB2 or somatic (s) BRCA mutations (sBRCAm). Here we report results from the expansion cohorts in a larger sample of pts with gPALB2m or sBRCAm. METHODS: Eligible pts had MBC of any subtype with measurable disease and a gPALB2m or sBRCAm. Pts received olaparib 300 mg twice a day until progression. The primary end point was overall response rate. Secondary end points include clinical benefit rate (CBR) at 18 weeks, progression-free survival (PFS), duration of response (DOR), and whether among sBRCAm carriers the mutant allele frequency (MAF) is significantly higher in responders than in nonresponders. RESULTS: Fifty-four pts with gPALB2m (N = 24) or sBRCAm (N = 30) were enrolled. Forty-two (78%) had estrogen receptor-positive human epidermal growth factor receptor 2-negative (HER2-) MBC, seven (13%) had triple-negative breast cancer, and five (9%) had HER2+ disease. Among pts with a gPALB2m, the overall response rate (ORR) was 75% (80% CI, 60.2 to 86.3), CBR was 83.3% (90% CI, 65.8 to 94.1), the median PFS was 9.4 months (90% CI, 8.3 to 13.1), and the median DOR was 7.0 months (90% CI, 5.6 to 10.4). Among pts with sBRCAm (15 sBRCA1 and 15 sBRCA2), the ORR was 36.7% (80% CI, 24.7 to 50), CBR was 53.3% (90% CI, 37 to 69.1), the median PFS was 5.5 months (90% CI, 2.8 to 8.3), and the median DOR was 11.2 months (90% CI, 4.4 to not reached). One additional pt had an unconfirmed partial response. Although clinically meaningful, the ORR in pts with sBRCAm did not achieve the prespecified target. Among sBRCAm carriers, the mean MAF did not differ significantly between responders (46%) and nonresponders (39%; P = .7). CONCLUSION: Olaparib is active in pts with MBC with gPALB2m and sBRCAm, significantly expanding the population of pts with breast cancer likely to benefit from PARP inhibitors beyond gBRCA1/2m carriers.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tung NM, Robson ME, Li T, et al. TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2. J Clin Oncol. 2026. PMID: 41604601. doi:10.1200/JCO-25-02075

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。